These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28618436)

  • 1. More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy.
    Guy S; Van Veen J; Kitchen S
    Semin Thromb Hemost; 2017 Sep; 43(6):642-643. PubMed ID: 28618436
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: "More on the Limitations of the aPTT for Monitoring Argatroban Therapy".
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Sep; 43(6):644. PubMed ID: 28609797
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time.
    Keyl C; Lehane C; Zimmer E; Trenk D
    Thromb Haemost; 2016 Nov; 116(6):1180-1181. PubMed ID: 27628460
    [No Abstract]   [Full Text] [Related]  

  • 5. Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.
    Guy S; Kitchen S; Van Veen JJ
    Br J Haematol; 2018 Feb; 180(4):594-597. PubMed ID: 27785784
    [No Abstract]   [Full Text] [Related]  

  • 6. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
    John TE; Hallisey RK
    Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombelastography in a patient with heparin-induced thrombocytopenia treated with argatroban.
    Zayac EA; Pivalizza EG; Levine RL
    Anesth Analg; 2008 Jan; 106(1):351-2. PubMed ID: 18165611
    [No Abstract]   [Full Text] [Related]  

  • 9. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
    Hursting MJ; Verme-Gibboney CN
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.
    Rice L; Hursting MJ; Baillie GM; McCollum DA
    J Clin Pharmacol; 2007 Aug; 47(8):1028-34. PubMed ID: 17525167
    [No Abstract]   [Full Text] [Related]  

  • 15. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
    Shapiro NL; Durr EA; Krueger CD
    Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case series describing the use of argatroban in patients on extracorporeal circulation.
    Cornell T; Wyrick P; Fleming G; Pasko D; Han Y; Custer J; Haft J; Annich G
    ASAIO J; 2007; 53(4):460-3. PubMed ID: 17667231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
    Pendleton R; Wheeler MM; Rodgers GM
    Ann Pharmacother; 2006 May; 40(5):972-6. PubMed ID: 16569813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices.
    Samuels LE; Kohout J; Casanova-Ghosh E; Hagan K; Garwood P; Ferdinand F; Goldman SM
    Ann Thorac Surg; 2008 May; 85(5):1651-5. PubMed ID: 18442558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.